• Home
  • News
  • Calendar
  • About DF/HCC
  • Membership
  • Visitor Center

Omid C. Farokhzad, MD

Associate Professor, Department of Anesthesia, Harvard Medical School

Director, Laboratory of Nanomedicine and Biomaterials, Anaesthesia, Brigham And Women's Hospital

Contact Info

Omid Farokhzad
Brigham And Women's Hospital
75 Francis Street
Boston, MA, 02115
Mailstop: MRB611
Phone: 617-732-6093
Fax: 617-730-2801
ofarokhzad@zeus.bwh.harvard.edu

Assistant

Susan Fountain
Administrative Secretary
Anesthesiology, Perioperative and Pain Medicine
Brigham & Women's Hospital
75 Francis St
Boston, MA, 02115
Phone: 617-732-7362
sfountain@partners.org

DF/HCC Program Affiliation

Prostate Cancer
Cancer Cell Biology

Lab Website

Laboratory of Nanomedicine and Biomaterials

Research Abstract

Omid Farokhzad is an Associate Professor at Harvard Medical School (HMS) and a physician-scientist at Brigham and Women’s Hospital (BWH). Dr. Farokhzad directs the Laboratory of Nanomedicine and Biomaterials at BWH. He is a faculty member of the Brigham Research Institute Cancer Research Center and a member of the Dana Farber/Harvard Cancer Center. Dr. Farokhzad’s research is focused on the development of therapeutic nanoparticle technologies; most notably, he pioneered the high throughput combinatorial development and screening of multifunctional nanoparticles for medical applications. Dr. Farokhzad has authored approximately 110 papers and holds more than 135 issued/pending US and International patents. The technologies that Dr. Farokhzad has developed with collaborators at HMS and MIT have formed the basis for: 1) a new class of targeted nanoparticles for treatment of important human diseases including cancer and cardiovascular disease; 2) a new class of synthetic nanoparticle vaccines for prophylactic and therapeutic applications and 3) a new class of integrative combination nanomedicines for synergistic treatment of cancers, inflammation/pain, and infectious diseases. These technologies formed the foundational platform for the launch of three biotechnology companies: BIND Therapeutics (NASDAQ: BIND), Selecta Biosciences, Blend Therapeutics, which are translating the aforementioned academic innovations toward commercialization and societal impact. Dr. Farokhzad was elected to the College of the Fellows of the American Institute of Medical and biological Engineering. He was a recipient of the 2013 RUSNANOPRIZE, one of the largest international nanotechnology prizes, for the development and industrialization of nanoparticle technologies for medical applications. In 2013, the Boston Globe selected him among the top innovators in Massachusetts and the Boston Business Journal selected him among the Health Care Champions for his innovations. In 2012, he was among the regional Ernst & Young Entrepreneur of the Year awardees. Dr. Farokhzad completed his post-graduate clinical and post-doctoral research trainings, respectively, at the BWH/HMS and MIT in the laboratory of Institute Professor Robert Langer. He received his M.D. and M.A. from Boston University School of Medicine.

Publications

View All Publications